Our current meta-analyses including 5,093 patients from high quality phase 3 RCTs is thus the largest meta-analysis of PD-1/PD-L1 inhibitors in pretreated advanced cancer patients and provides a more reliable and higher quality evidence for judging the efficacy of treatment with PD-1/PD-L1 inhibitors. Here, PDCD1 is linked to cancer.